Leavenworth CMOP 11 PHARMACEUTICALS

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 15 is conducting a Sources Sought Notice for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) pharmaceutical procurement. The agency is seeking potential manufacturers or distributors capable of providing 11 specific pharmaceutical products, including medications such as Galantamine Hydrobromide, Hydrocortisone, HCTZ/Valsartan, Imiquimod, and Lithium Carbonate. Interested vendors must submit responses by March 18, 2025, at 16:00 CDT to contract specialist Sarah Fry via email. The market research requires respondents to provide comprehensive company details, including socioeconomic categories, domestic manufacturing confirmation, authorized distributors, average prescription costs, and applicable contract schedule numbers. Evaluation will focus on vendors' ability to meet domestic manufacturing requirements, product availability, and compliance with the specified NAICS code 325412 for Pharmaceutical Preparation Manufacturing.

The procurement does not have a specific set-aside designation, indicating potential opportunities for both small and large businesses. The notice represents a market research effort and is not a formal solicitation, meaning no immediate contract award is guaranteed. Vendors must demonstrate they meet the business size standard of 1,250 employees for the specified NAICS code. The procurement covers pharmaceutical products for the VA's Consolidated Mail Outpatient Pharmacy, suggesting a potential significant volume of pharmaceutical supplies for veterans' healthcare needs. While specific award values are not disclosed, the comprehensive nature of the request implies a substantial procurement opportunity for qualified pharmaceutical manufacturers and distributors with the capability to provide multiple medication types domestically.